Ropes & Gray grows FDA practice
Bennett, Turner & Coleman D.C. law firm will merge into Ropes & Gray's Health and Life Sciences Practices. Ropes & Gray, which employs two attorneys in its FDA practice, will gain BT&C's 11 attorneys with expertise in FDA regulatory issues. During a House Commerce/Oversight Subcommittee hearing on ImClone's Erbitux, a Bristol exec testified that Bennett, Turner & Coleman partner Alan Bennett informed him that a refuse-to-file letter from FDA was imminent (1"The Pink Sheet" June 17, p. 5)...
You may also be interested in...
The House Energy & Commerce Committee is interested in looking further into FDA's authority to "rein in" pre-approval promotions
Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.